Tigermed, a China Clinical Stage CRO, Schedules ChiNext IPO

by Richard Daverman, PhD

July 31, 2012 -- Tigermed Consulting, the clinical stage CRO headquartered in Hangzhou, will stage an IPO on the ChiNext exchange. The company will offer 13.4 million A shares, which will constitute 25% of the company expanded share base. The company plans to price the offering next week on August 6. More details,,,,

Back to news